Stephanie M Kochav1, Hasan Garan1, Lyall A Gorenstein2, Elaine Y Wan1, Hirad Yarmohammadi3,4. 1. Department of Medicine, Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA. 2. Department of Surgery, New York Presbyterian Hospital, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA. 3. Department of Medicine, Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA. hy2567@cumc.columbia.edu. 4. Cardiology and Cardiac Electrophysiology, Columbia University, 177 Fort Washington Avenue New York, New York, NY, 10032, USA. hy2567@cumc.columbia.edu.
Abstract
BACKGROUND: The autonomic nervous system contributes to the pathogenesis of ventricular arrhythmias (VA). Though anti-arrhythmic drug therapy and catheter ablation are the mainstay of management of VAs, success may be limited in patients with more refractory arrhythmias. Sympathetic modulation is increasingly recognized as a valuable adjunct tool for managing VAs in patients with structural heart disease and inherited arrhythmias. RESULTS: In this review, we explore the role of the sympathetic nervous system and rationale for cardiac sympathetic denervation (CSD) in VAs and provide a disease-focused review of the utility of CSD for patients both with and without structural heart disease. CONCLUSIONS: We conclude that CSD is a reasonable therapeutic option for patients with VA, both with and without structural heart disease. Though not curative, many studies have demonstrated a significant reduction in the burden of VAs for the majority of patients undergoing the procedure. However, in patients with unilateral CSD and subsequent VA recurrence, complete bilateral CSD may provide long-lasting reprieve from VA.
BACKGROUND: The autonomic nervous system contributes to the pathogenesis of ventricular arrhythmias (VA). Though anti-arrhythmic drug therapy and catheter ablation are the mainstay of management of VAs, success may be limited in patients with more refractory arrhythmias. Sympathetic modulation is increasingly recognized as a valuable adjunct tool for managing VAs in patients with structural heart disease and inherited arrhythmias. RESULTS: In this review, we explore the role of the sympathetic nervous system and rationale for cardiac sympathetic denervation (CSD) in VAs and provide a disease-focused review of the utility of CSD for patients both with and without structural heart disease. CONCLUSIONS: We conclude that CSD is a reasonable therapeutic option for patients with VA, both with and without structural heart disease. Though not curative, many studies have demonstrated a significant reduction in the burden of VAs for the majority of patients undergoing the procedure. However, in patients with unilateral CSD and subsequent VA recurrence, complete bilateral CSD may provide long-lasting reprieve from VA.
Authors: Seongwook Han; Kenzaburo Kobayashi; Boyoung Joung; Gianfranco Piccirillo; Mitsunori Maruyama; Harry V Vinters; Keith March; Shien-Fong Lin; Changyu Shen; Michael C Fishbein; Peng-Sheng Chen; Lan S Chen Journal: J Am Coll Cardiol Date: 2012-03-06 Impact factor: 24.094
Authors: J M Cao; M C Fishbein; J B Han; W W Lai; A C Lai; T J Wu; L Czer; P L Wolf; T A Denton; I P Shintaku; P S Chen; L S Chen Journal: Circulation Date: 2000-04-25 Impact factor: 29.690
Authors: J M Cao; L S Chen; B H KenKnight; T Ohara; M H Lee; J Tsai; W W Lai; H S Karagueuzian; P L Wolf; M C Fishbein; P S Chen Journal: Circ Res Date: 2000-04-14 Impact factor: 17.367
Authors: Sébastien P J Krul; Wouter R Berger; Marieke W Veldkamp; Antoine H G Driessen; Arthur A M Wilde; Thomas Deneke; Jacques M T de Bakker; Ruben Coronel; Joris R de Groot Journal: JACC Clin Electrophysiol Date: 2015-10-24
Authors: Olujimi A Ajijola; Jonathan J Wisco; H Wayne Lambert; Aman Mahajan; Elena Stark; Michael C Fishbein; Kalyanam Shivkumar Journal: Circ Arrhythm Electrophysiol Date: 2012-08-23